3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
670
Carcinoma, Non-Small-Cell Lung
464
Prostatic Neoplasms
390
Neoplasms
385
Lung Neoplasms
266
Multiple Myeloma
246
Colorectal Neoplasms
233
Neoplasm Metastasis
217
Melanoma
203
Ovarian Neoplasms
166
Leukemia, Myeloid, Acute
166
Pancreatic Neoplasms
154
Carcinoma, Renal Cell
142
Squamous Cell Carcinoma of Head and Neck
140
Lymphoma
135
Brain Neoplasms
131
Leukemia, Lymphocytic, Chronic, B-Cell
126
Glioblastoma
126
Lymphoma, Non-Hodgkin
123
Recurrence
121
Carcinoma, Hepatocellular
119
Head and Neck Neoplasms
115
Urinary Bladder Neoplasms
111
Triple Negative Breast Neoplasms
110
Stomach Neoplasms
109
Precursor Cell Lymphoblastic Leukemia-Lymphoma
104
Uterine Cervical Neoplasms
101
Hematologic Neoplasms
101
Lymphoma, Follicular
96
Sarcoma
95
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Biochemically Recurrent Prostate Cancer
×
1 year
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled